CREBBP and acute myeloid leukemia: Mechanistic studies revealed the selective EP300/CREBBP inhibitor disrupting the binding of MLL-r-BET transcriptional complex to H3K27Ac modification on some certain critical gene loci to inhibit MLL-r AML cells proliferation, independent of their global histone acetylation status.